AstraZeneca PLC (AZN) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
AZN Revenue Growth
Revenue Breakdown (FY 2025)
AZN's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
AZN Revenue Analysis (2014–2025)
As of May 6, 2026, AstraZeneca PLC (AZN) generated trailing twelve-month (TTM) revenue of $60.44 billion, reflecting strong growth of +12.5% year-over-year. The most recent quarter (Q1 2026) recorded $15.29 billion in revenue, down 1.4% sequentially.
Looking at the longer-term picture, AZN's 5-year compound annual growth rate (CAGR) stands at +17.2%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $58.74 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows AZN's business is primarily driven by Total Oncology (24%), CVRM (13%), and Rare Disease (9%).
When compared to Healthcare sector peers including PFE (+1.4% YoY), MRK (+1.2% YoY), and LLY (+47.4% YoY), AZN has underperformed the peer group in terms of revenue growth. Compare AZN vs PFE →
AZN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| AZNCurrent | $60.4B | +12.5% | +17.2% | 23.4% | |
 PFE | $62.6B | +1.4% | +8.5% | 24.7% | |
 MRK | $64.9B | +1.2% | +9.4% | 36.2% | |
 LLY | $65.2B | +47.4% | +21.6% | 45.6% | |
 BMY | $48.2B | +1.8% | +2.5% | 26.3% | |
 ABBV | $61.2B | +8.6% | +6.0% | 32.8% |
AZN Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $58.74B | +8.6% | $48.11B | 81.9% | $13.74B | 23.4% |
| 2024 | $54.07B | +18.0% | $43.87B | 81.1% | $10.00B | 18.5% |
| 2023 | $45.81B | +3.3% | $37.54B | 82.0% | $8.19B | 17.9% |
| 2022 | $44.35B | +18.5% | $31.96B | 72.1% | $3.76B | 8.5% |
| 2021 | $37.42B | +40.6% | $24.98B | 66.8% | $1.06B | 2.8% |
| 2020 | $26.62B | +9.2% | $21.32B | 80.1% | $5.16B | 19.4% |
| 2019 | $24.38B | +10.4% | $19.46B | 79.8% | $2.92B | 12.0% |
| 2018 | $22.09B | -1.7% | $17.15B | 77.7% | $3.39B | 15.3% |
| 2017 | $22.46B | -2.3% | $18.15B | 80.8% | $3.68B | 16.4% |
| 2016 | $23.00B | -6.9% | $18.88B | 82.1% | $4.90B | 21.3% |
Full AZN Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Should I Buy AZN Right Now?
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
See AZN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AZN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AZN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAZN — Frequently Asked Questions
Quick answers to the most common questions about buying AZN stock.
Is AZN's revenue growth accelerating or slowing?
AZN maintains +12.5% revenue growth, in line with its 5-year CAGR of +17.2%. TTM revenue stands at $60.4B. Growth rate remains consistent with historical average.
What is AZN's long-term revenue growth rate?
AstraZeneca PLC's 5-year revenue CAGR of +17.2% reflects the sustained expansion pattern. Current YoY growth of +12.5% is near this long-term average.
How is AZN's revenue distributed by segment?
AZN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.